Post Reply
481-500 of 1050
the best is side line 1st with this stock, bcos the TA is shown still on the way to go down, since the news are stated that way, now the markets we have to play safe rather then gamble. If you base on TA to play share u sure can earn $$. What for take the risk of 50/50%. Base on TA u have a chance of abt 80% wining. just play catious, n do research, good luck.
The company has announced that even if they lose the law suit, is financial results would have no adverse effects. That means if it loses the suit, say plus costs upto $5 million, it is still ok, if we analyse the statement.
But if it wins, then it means the share will spring up, barring any other untoward events arising.
It is a good risk if it fall below 45 cents because the demand for clean water projects is still increasing worldwide, but I don't know if the company is still into it. This type of business can give good profits.
I would think it is safer to collect small amounts and hold until the coast is clear.
rights issue aborted, dwlinding profit margin BOT projects,potential legal suit again and broke thru 50cts level-potential credit crunch as it may not be able to pay the covertible bond (CB)holders...likely will go below its ipo price of 46cts like most penny s stocks..trade with care plse..avoid..can become even cheaper
787180 ( Date: 20-Mar-2008 11:23) Posted:
|
Bio-Treat clarified that, based on legal advice that it has obtained, it is in a position, and fully intends, to vigorously defend the allegations made by Abax Lotus.
The Company is of the opinion that the alleged claims made by Abax Lotus and its outcome, even if adverse to the Company, will not have any material adverse impact on the financial results of the Company for the financial year ending 30 June 2008.
their charts look bad enough already...now with more negative news...
more bad news??
A Hong Kong-based hedge fund has sued
guarantors to recover US$4.2 million allegedly owed to it as damages for the collapse of
their credit agreement. According to court documents obtained by BT, Abax Lotus, a
fund run by Abax Global Capital, filed its complaint with the New York State Supreme
Court on March 10. The complaint - filed through legal counsel Skadden, Arps, Slate,
Meagher & Flom LLP - alleges that the credit agreement signed on Jan 23 collapsed
because Bio-Treat failed to follow through on terms agreed. Under the agreement, Bio-
Treat was said to have agreed to issue Abax Lotus up to 543 million yuan (S$106.6
million) of US dollar settled senior secured notes due 2013, bundled with detachable
warrants which, if fully exercised, would have raised up to about $130 million for Bio-
Treat and leave Abax Lotus with some 16% stake in Bio-Treat. (BT)
Is it true the rights issue aborted? at 45 to 47cts can actually buy as I bought at this price and even higher b4 and sold most of the time for gd profits
ekekeg ( Date: 21-Mar-2008 11:53) Posted:
|
Ya, saw the news too but not stated that Bio-treat won the legal suit.
saw some very brief info on Sharejunction's "Market Bites"
News from where??
Lucky for those vested and did not sell off. I see double happiness for the counter. Won legal suit and grab big contracts. I must change my view of this counter. Shortists better cover quickly!!! Good bet now..
I think companies that need to constantly borrow money for growth will be hit now as this is a credit crisis. The same with the Reits, they should be heading for big time.
Just my thought.
Dealers shot it down probably in anticipation of warrant issue strike price 76 cents to rights at 5 cents and bond issue. Both are now cancelled, but the shortists have not yet cover since shorting all way down from 59 cents.
Enough profits already for shortists, and should see them cover with the strong show on DOW on Thursday.
Expect rebound tho it has made new lows at lower bollinger band. Kill it if it does go above 50 cents.
Tis one a goner...
Sign...
Have been hovering 55 to 65cts for some time finally this China stock got whack down..more downside expected like China energy,Hengxin,Yangzijiang,synear,...looks like its rights issue at 52cts may not go thru..anyone knows its AGM date
Poised for a rebound
Source: OCBC
- Bio-treat has fallen into the support level as per our forecast on 19 Feb.
- The support level around S$0.56 is in proximity to the lower band of the
downtrend channel and should provide added strength to the support around
the S$0.54 - 0.56 range.
- We also observed the formation of reversal candlestick yesterday on the
back of high volume, suggesting that Bio-treat is attempting to reverse its
trend at this juncture.
- The stochastic indicator has fallen into oversold region, indicating that the
price is poised for a rebound.
- Any rebound hereon would meet with resistance at S$0.70, which is in
proximity to the 50 and 100-day moving averages and is also a level around
that the stock had consolidated over the last 12 months.
- Bio-treat has fallen into the support level as per our forecast on 19 Feb.
- The support level around S$0.56 is in proximity to the lower band of the
downtrend channel and should provide added strength to the support around
the S$0.54 - 0.56 range.
- We also observed the formation of reversal candlestick yesterday on the
back of high volume, suggesting that Bio-treat is attempting to reverse its
trend at this juncture.
- The stochastic indicator has fallen into oversold region, indicating that the
price is poised for a rebound.
- Any rebound hereon would meet with resistance at S$0.70, which is in
proximity to the 50 and 100-day moving averages and is also a level around
that the stock had consolidated over the last 12 months.
Most S stocks down a lot except Biotreat...artifically prop up by its impending rights issue at 52cts...see solid stocks like Sino Environ and Epure..the latter after ex 3 for 1 share splits drop below its theoretical ex price of 60cts( cum scripts was $1.80)
any body can comment on this hammer (with a small pin on it) formed today ? will it be sustainable? of cos provided DOW JONES in green Zone,,,,,,
Market negative on rights issue
Buy near 52cts the rights issue price...but I think 55cts shd be ok
Source: UBS
�� One for three rights issue
BioTreat proposed a one for three rights issue at an issue price of S$0.525 on 18 Febuary 2008. The aim of this S$156m funding is to help retire S$206m worth of convertible bonds. The theoretical ex-price is S$0.69.
�� Share price has retreated 9% in two sessions
The market has reacted negatively to the news because the company had announced on 23 January a funding plan that would have been used to partially redeem the convertible bonds. It looks like that funding failed to close. Also, the rights issue is not being offered to investors who have registered addresses outside of Singapore.
�� Demand for BioTreat?s services remain strong
BioTreat?s pipeline remains strong and if it is able to complete the fund raising successfully, it would be in a position to compete for newer BOT/TOT projects. It currently has 14 BOT/TOT projects in its portfolio worth around RM2.15bn. When completed this would provide a source of recurring avenue.
�� Valuation
The stock trades at 7.5x calenderised 2008E earnings versus a historical 12x. Our 12-month price target of S$1.04 is derived using a DCF methodology and assumes a WACC of 7.7% and terminal growth of 3%
�� One for three rights issue
BioTreat proposed a one for three rights issue at an issue price of S$0.525 on 18 Febuary 2008. The aim of this S$156m funding is to help retire S$206m worth of convertible bonds. The theoretical ex-price is S$0.69.
�� Share price has retreated 9% in two sessions
The market has reacted negatively to the news because the company had announced on 23 January a funding plan that would have been used to partially redeem the convertible bonds. It looks like that funding failed to close. Also, the rights issue is not being offered to investors who have registered addresses outside of Singapore.
�� Demand for BioTreat?s services remain strong
BioTreat?s pipeline remains strong and if it is able to complete the fund raising successfully, it would be in a position to compete for newer BOT/TOT projects. It currently has 14 BOT/TOT projects in its portfolio worth around RM2.15bn. When completed this would provide a source of recurring avenue.
�� Valuation
The stock trades at 7.5x calenderised 2008E earnings versus a historical 12x. Our 12-month price target of S$1.04 is derived using a DCF methodology and assumes a WACC of 7.7% and terminal growth of 3%
Buy near 52cts the rights issue price...but I think 55cts shd be ok
interesting counter at the moment looking at the sell and buy queues...the market depth..always 1 bid of a difference
| Time | Last | Volume | Buy/Sell |
| 10:08:09 | 0.750 | 42,000 | Buy Up |
| 10:07:51 | 0.745 | 5,000 | Sell Down |
| 10:07:13 | 0.750 | 7,000 | Buy Up |
| 10:06:53 | 0.750 | 53,000 | Buy Up |
| 10:01:29 | 0.745 | 12,000 | Buy Up |
| 10:01:00 | 0.740 | 14,000 | Buy Up |
| 09:58:26 | 0.740 | 2,000 | Buy Up |
| 09:58:02 | 0.740 | 1,000 | Buy Up |
| 09:57:29 | 0.740 | 12,000 | Buy Up |
| 09:56:22 | 0.740 | 4,000 | Buy Up |
| 09:56:20 | 0.735 | 30,000 | Sell Down |
| 09:51:23 | 0.735 | 4,000 | Sell Down |
| 09:47:01 | 0.740 | 17,000 | Buy Up |
| 09:46:39 | 0.740 | 5,000 | Buy Up |
| 09:45:00 | 0.735 | 5,000 | Sell Down |
| 09:44:46 | 0.735 | 5,000 | Buy Up |
| 09:44:42 | 0.735 | 7,000 | Buy Up |
| 09:42:25 | 0.730 | 100,000 | Buy Up |
| 09:40:09 | 0.710 | 5,000 | Sell Down |
| 09:38:49 | 0.710 | 1,000 | Sell Down |